For decades, people living with ME/CFS (Myalgic Encephalomyelitis / Chronic Fatigue Syndrome) have waited for treatments that address more than just symptoms. Now, new research led by Dr. Avik Roy at the Simmaron Research Institute suggests that an unexpected molecule—rapamycin—might help restore the underlying biology that drives fatigue in many patients. Why Rapamycin? A Closer…

Low-dose rapamycin shows promising results in rapamycin ME/CFS patients, improving fatigue, stamina, and immune balance. Could this be a breakthrough ME/CFS treatment rapamycin option for chronic fatigue syndrome? Insights from longevity research, including studies such as this overview of rapamycin’s benefits, are helping expand interest in its therapeutic potential. ME/CFS: A Condition Still Waiting for…

Rapamycin has long been studied as a potential rapamycin anti aging therapy—something explored in detail in resources like this longevity overview. But in 2025, the spotlight is shifting toward new and unexpected research directions—far beyond its classic role in slowing aging. Here are some of the most intriguing and lesser-known findings emerging this year, especially…

Early results from a phase 1 clinical trial suggest that weekly administration of rapamycin may significantly improve patient-reported outcome measures (PROMs) in individuals living with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). This emerging rapamycin ME/CFS trial adds to growing evidence around low-dose rapamycin for ME/CFS patients and highlights increasing interest in rapamycin as a potential option…